Parameter | Total | KTX-HD | KTX | |
---|---|---|---|---|
DAA-KTX | KTX-DAA | |||
Patients | 26 | 11 | 7 | 8 |
Age, years [mean ± SD] | 49.0 ± 9.6 | 52.6 ± 10.0 | 39.7 ± 5.5 | 52.1 ± 6.6 |
Gender (male) [n (%)] | 19 (73.1) | 8 (72.7) | 5 (71.4) | 6 (75.0) |
Transplant frequency [n (%)] | ||||
1 | 12 (46.2) | 6 (54.5) | 2 (28.6) | 4 (50.0) |
2 | 12 (46.2) | 5 (45.5) | 4 (57.1) | 3 (37.5) |
≥3 | 2 (7.7) | 0 (0.0) | 1 (14.3) | 1 (12.5) |
HCV genotype [n (%)] | ||||
1b | 21 (80.8) | 10 (90.9) | 5 (71.4) | 6 (75.0) |
2a | 5 (19.2) | 1 (9.1) | 2 (28.6) | 2 (25.0) |
Cirrhosis [n (%)] | 1 (3.8) | 0 (0.0) | 0 (0.0) | 1 (12.5) |
Immunosuppressive regimens [n (%)] | ||||
Triple-therapy | 18 (69.2) | 3 (27.3) | 7 (100.0) | 8 (100.0) |
Double-therapy | 6 (23.1) | 6 (54.5) | 0 (0.0) | 0 (0.0) |
Monotherapy | 2 (7.7) | 2 (18.2) | 0 (0.0) | 0 (0.0) |
DAAs regimens [n (%)] | ||||
SOF | 1 (3.8) | 0 (0.0) | 1 (14.3) | 0 (0.0) |
SOF + LDV | 17 (65.4) | 8 (72.7) | 4 (57.1) | 5 (62.5) |
SOF + DCV | 8 (30.8) | 3 (27.3) | 2 (28.6) | 3 (37.5) |
Viral load, log10 IU/ml [mean ± SD] | 6.5 ± 1.3 | 5.9 ± 1.1 | 6.5 ± 0.5 | 7.2 ± 1.6 |
Treatment cycle, weeks [median (range)] | 12 (12-12) | 12 (12-12) | 12 (12-12) | 12 (12-24) |